Viruses, Vol. 13, Pages 317: Viral Vectors for COVID-19 Vaccine Development
Viruses, Vol. 13, Pages 317: Viral Vectors for COVID-19 Vaccine Development
Viruses doi: 10.3390/v13020317
Authors:
Kenneth Lundstrom
Vaccine development against SARS-CoV-2 has been fierce due to the devastating COVID-19 pandemic and has included all potential approaches for providing the global community with safe and efficient vaccine candidates in the shortest possible timeframe. Viral vectors have played a central role especially using adenovirus-based vectors. Additionally, other viral vectors based on vaccinia viruses, measles viruses, rhabdoviruses, influenza viruses and lentiviruses have been subjected to vaccine development. Self-amplifying RNA virus vectors have been utilized for lipid nanoparticle-based delivery of RNA as COVID-19 vaccines. Several adenovirus-based vaccine candidates have elicited strong immune responses in immunized animals and protection against challenges in mice and primates has been achieved. Moreover, adenovirus-based vaccine candidates have been subjected to phase I to III clinical trials. Recently, the simian adenovirus-based ChAdOx1 vector expressing the SARS-CoV-2 S spike protein was approved for use in humans in the UK.
Source: Viruses - Category: Virology Authors: Kenneth Lundstrom Tags: Review Source Type: research
More News: Adenoviruses | Clinical Trials | COVID-19 | Flu Pandemic | Influenza | Influenza Vaccine | Measles | Measles Vaccine | Nanotechnology | Pandemics | SARS | Vaccines | Veterinary Vaccinations | Virology